Endpoints News
Plus: Hinge buys digestive health startup Read in browser
Endpoints News
Thursday, 6 August 2026
Thank you for reading, dupa dupackia!
basic
UPGRADE
sponsored by ZS
Beyond the prescription: Eliminating barriers to care
For many patients, the hardest part of care begins after a therapy decision is made. Delays, handoffs and fragmented processes create barriers that stand between patient need and patient outcome. ZS examines how biopharma can create "zero distance to the patient" by redesigning care delivery, reducing friction and removing the coordination burden patients often carry themselves.
Explore zero distance
Joining forces
“Great growth rate, small numbers,” is how Centene CEO Sarah London described enrollment in its ICHRA business last month, during the insurer's earnings call.
ICHRA, or individual coverage health reimbursement arrangements, are a new-ish way for employers to finance health insurance. Instead of providing a traditional group health plan, companies contribute pre-tax money to these accounts so workers can buy coverage on their own in the individual market.
But adoption has been slow since ICHRA (pronounced "ICK-ruh") first became an option in 2020. At Centene, roughly 50,000 people are enrolled through those arrangements. That's 2.5 times more than the year prior. But it's still less than 1% of the company’s total insurance membership.
Employers are wary of big benefit shifts, and there hasn't been a ton of awareness of the ICHRA option. Plus, there have been some operational and technical issues with the model. One problem is this: Over the past several years, dozens of companies, fueled by VC funds, popped up to help employers move to ICHRAs. To enroll these workers in plans, each vendor has to send enrollment and payment information to the insurer, and each insurer wants it differently. It’s a headache, and it makes it hard for administrators to scale.
“All the ICHRA platforms that are emerging are dealing with this same challenge, where it's kind of a mess under the hood,” Kyle Estep, an ICHRA expert, told me.
Estep is the CEO of a new company just launched to fix that problem. Called ICHRAx and backed by health insurer Oscar and administrators such as Take Command and zizzl, it’s meant to help with the backend of ICHRA administration, which has been like the Wild West, Estep explained.
ICHRAx will act as a data exchange layer between administrators and health insurers. Instead of having to integrate with each insurance company, administrators will send data to ICHRAx to pass along. Insurers will plug into ICHRAx, connecting them to the administrators. The effort is also meant to get the industry to agree on some enrollment and billing standards. It goes live in a couple of weeks.
Estep told me he doesn’t think these back-end data exchange problems have been a huge dampener on ICHRA’s adoption so far. I’ve reported on other challenges it’s facing, like premium increases in the individual insurance market. But as momentum behind the ICHRA concept picks up, “if we don't start working on this now collectively and start to figure out these standards in the years ahead, it will ultimately become a rate-limiting factor of how far this market can go,” he said.
It’s fascinating to see competitors come together to address an issue they all have a vested interest in fixing. Time will tell if it works.
- Shelby
Here’s what’s new
Hinge Health will buy Cylinder Health for $105M to enter digestive care
Hinge Health is ac­quir­ing di­ges­tive health start­up Cylin­der Health, as the vir­tu­al phys­i­cal ther­a­py com­pa­ny ex­pands to treat more chron­ic con­di­tions.
Demis Hassabis says he's 'leaning into' Isomorphic role amid Alphabet and DeepMind shakeup
Al­pha­bet is shak­ing up its AI lead­er­ship, with Demis Has­s­abis step­ping down as CEO of Google Deep­Mind and be­com­ing Al­pha­bet's chief sci­en­tist. Long­time Google chief sci­en­tist Jeff Dean is leav­ing to build his own start­up.
Quote of the week
I don't think that they'll ever be able to get away completely from the gray and black market.
Mark Mikhail, CEO of compounder Olympia Pharmaceuticals, speaking about health and wellness peptides during Endpoints News' Manufacturing Day 2026.
This week in health Тech

CVS’ second-quarter earnings beat Wall Street estimates across the board and it raised its 2026 outlook to at least $414 billion in revenue. The company's insurance arm, Aetna, spent less on patient care than expected as Medicare Advantage plans stabilized, while its retail pharmacy business also did well, thanks to its acquisition of Rite Aid assets last year. The company also announced that it will work with Eli Lilly to make it easier for patients to access weight loss drugs through CVS.

Amae Health, a startup that treats severe mental illness, is working with Google to incorporate Fitbit data into treatment so doctors can detect early signs of relapse and more continuously monitor patients in between appointments.

Consumer goods giant Procter & Gamble is buying supplement company Thorne for $3.8 billion as consumer wellness continues to gain traction.

Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.
Unsubscribe preferences
Unsubscribe from all newsletters
FT Specialist Logo A service from the Financial Times